CareDx (CDNA) Expected to Announce Quarterly Earnings on Wednesday

CareDx (NASDAQ:CDNA - Get Free Report) is expected to be releasing its earnings data after the market closes on Wednesday, February 26th. Analysts expect CareDx to post earnings of $0.05 per share and revenue of $84.56 million for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.

CareDx Price Performance

NASDAQ:CDNA traded down $1.09 during mid-day trading on Friday, hitting $22.29. 898,901 shares of the company's stock were exchanged, compared to its average volume of 858,255. CareDx has a one year low of $7.42 and a one year high of $34.84. The business has a fifty day moving average price of $22.69 and a 200 day moving average price of $25.40. The company has a market cap of $1.20 billion, a PE ratio of -8.26 and a beta of 1.87.

Insider Activity

In other news, Director Peter Maag sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the transaction, the director now directly owns 330,024 shares of the company's stock, valued at $8,250,600. The trade was a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CDNA. BTIG Research dropped their price objective on shares of CareDx from $40.00 to $35.00 and set a "buy" rating on the stock in a research note on Tuesday, November 5th. Wells Fargo & Company raised shares of CareDx from an "underweight" rating to an "equal weight" rating and dropped their price objective for the stock from $28.00 to $24.00 in a research note on Wednesday, January 15th. StockNews.com lowered shares of CareDx from a "buy" rating to a "hold" rating in a research note on Tuesday. Finally, HC Wainwright reaffirmed a "neutral" rating and issued a $26.00 target price on shares of CareDx in a report on Tuesday, January 14th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $28.33.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.